Safety of abacavir therapy after temporary interruptions in patients without hypersensitivity reactions to the drug

Juan Berenguer(Instituto de Salud Carlos III), José María Ruiz-Guiardin(Hospital Universitario de La Princesa), Vicente Estrada(Instituto de Salud Carlos III), Belén Padilla(Hospital General Universitario Gregorio Marañón), José María Kindelán(Hospital Universitario Reina Sofía), Peré Domingo(Hospital de Sant Pau), Carlos Martín-Cantera(Complejo Hospitalario de Cáceres)

AIDS

June 1, 2002

10.1097/00002030-200206140-00018

Cited by 9

Related Papers

Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy

|JAMA|2016|1.4k

Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study

|The Lancet|2019|1k

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19

|JAMA|2021|728

Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain

|Clinical Microbiology and Infection|2020|423

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

|The Lancet|2006|343